Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935028 | 0.93 | FFAR4 (0.49) | FFAR4ALOX5APFEN1GRM5HRH4 | |
| SCHEMBL25031311 | 0.91 | FFAR4 (0.48) | FFAR4ALOX5APFEN1GRM5CHRM4 | |
| SCHEMBL30479064 | 0.91 | FFAR4 (0.48) | FFAR4ALOX5APFEN1GRM5CHRM4 | |
| SCHEMBL25935090 | 0.91 | FFAR4 (0.52) | FFAR4CHRM4 | |
| SCHEMBL25819203 | 0.89 | FFAR4 (0.61) | FFAR4 | |
| SCHEMBL25935092 | 0.88 | FFAR4 (0.48) | FFAR4CHRM4 | |
| SCHEMBL25819206 | 0.86 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL25666797 | 0.86 | MAPT (0.38) | CHRM4HRH4 | |
| SCHEMBL25819403 | 0.84 | FFAR4 (0.42) | FFAR4GRM5HRH4 | |
| SCHEMBL25031334 | 0.84 | FFAR4 (0.47) | FFAR4ALOX5APFEN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | FFAR4 4754/4885ALOX5AP 3637/4885FEN1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.